Mediplantex National Pharmaceutical Past Earnings Performance
Past criteria checks 3/6
Mediplantex National Pharmaceutical's earnings have been declining at an average annual rate of -15.1%, while the Pharmaceuticals industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 1% per year. Mediplantex National Pharmaceutical's return on equity is 4.4%, and it has net margins of 3.5%.
Key information
-15.1%
Earnings growth rate
-43.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 13.0% |
| Revenue growth rate | 1.0% |
| Return on equity | 4.4% |
| Net Margin | 3.5% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Mediplantex National Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 418,048 | 14,696 | 68,908 | 0 |
| 31 Dec 23 | 399,965 | 11,837 | 68,918 | 0 |
| 30 Sep 23 | 404,917 | 11,906 | 71,303 | 0 |
| 30 Jun 23 | 408,625 | 12,229 | 68,920 | 0 |
| 31 Mar 23 | 409,334 | 12,334 | 68,749 | 0 |
| 31 Dec 22 | 401,051 | 6,366 | 70,666 | 0 |
| 30 Sep 22 | 351,553 | -994 | 58,493 | 0 |
| 30 Jun 22 | 322,353 | -2,586 | 57,400 | 0 |
| 31 Mar 22 | 322,863 | -5,265 | 58,455 | 0 |
| 31 Dec 21 | 343,951 | 3,747 | 59,184 | 0 |
| 30 Sep 21 | 411,377 | 18,418 | 67,503 | 0 |
| 31 Mar 21 | 472,634 | 21,198 | 81,817 | 0 |
| 31 Dec 20 | 521,391 | 24,422 | 89,651 | 0 |
Quality Earnings: MED has a high level of non-cash earnings.
Growing Profit Margin: MED's current net profit margins (3.5%) are higher than last year (3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MED's earnings have declined by 15.1% per year over the past 5 years.
Accelerating Growth: MED's earnings growth over the past year (19.2%) exceeds its 5-year average (-15.1% per year).
Earnings vs Industry: MED earnings growth over the past year (19.2%) exceeded the Pharmaceuticals industry -3.3%.
Return on Equity
High ROE: MED's Return on Equity (4.4%) is considered low.